ARKG Holdings of Cerus Corporation (CERS) - Updated Daily
Transplants and Blood Supply
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0.94% | $495.55m |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 34 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 37 | $3.26 |
| 🎫ARK Ownership Percent | |
| 3.53% | |
| Description | |
|---|---|
| Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. | |
| Website | |
| www.cerus.com |
Other ETFs That Hold CERS
Research Notes and Commentary for CERS
March 29, 2020
Convalescent Plasma Could Help in the Fight Against COVID-19
See Section #1January 27, 2020